ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Icosavax Inc

Icosavax Inc (ICVX)

15.31
0.00
(0.00%)
Closed June 12 4:00PM
15.31
0.00
( 0.00% )
Pre Market: 8:00PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
15.31
Bid
15.15
Ask
15.31
Volume
-
0.00 Day's Range 0.00
5.88 52 Week Range 16.105
Previous Close
15.31
Open
-
Last Trade
Last Trade Time
-
Average Volume (3m)
-
Financial Volume
-
VWAP
-

ICVX Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10000000CS
40000000CS
120000000CS
26-0.4-2.5461489497115.7116.10515.17126963315.46753432CS
524.9347.495183044310.3816.1055.8858605713.1843548CS
156-13.69-47.20689655172949.992.2839587512.29342317CS
260-13.69-47.20689655172949.992.2839587512.29342317CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
NCINeo Concept International Group Holdings Ltd
$ 1.05
(60.89%)
12.55M
LGHLWLion Group Holding Ltd
$ 0.0098
(44.12%)
1.05M
LGVNLongeveron Inc
$ 2.40
(32.60%)
7.19M
BRTXBioRestorative Therapies Inc
$ 1.66
(22.96%)
2.09M
DUOFangDD Network Group Ltd
$ 0.7369
(20.80%)
3.41M
IONMAssure Holdings Corporation
$ 0.2496
(-51.35%)
857.72k
CARACara Therapeutics Inc
$ 0.501
(-26.27%)
43.25k
APYXApyx Medical Corporation
$ 1.24
(-20.01%)
243
NAVINavient Corporation
$ 11.70
(-19.14%)
1
MTENMingteng International Corporation Inc
$ 3.90
(-18.58%)
2
NCINeo Concept International Group Holdings Ltd
$ 1.05
(60.89%)
12.55M
LGVNLongeveron Inc
$ 2.40
(32.60%)
7.19M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 8.51
(12.72%)
5.33M
DUOFangDD Network Group Ltd
$ 0.7369
(20.80%)
3.41M
TSLATesla Inc
$ 188.84
(6.51%)
2.97M

ICVX Discussion

View Posts
TheFinalCD TheFinalCD 6 months ago
AstraZeneca to Buy Icosavax for Up to $1.1 Bln

$ICVX
https://finance.yahoo.com/m/70b0bcc4-729d-378c-9f8c-27616ef35a3e/astrazeneca-to-buy-icosavax.html
👍️0
Jess070283 Jess070283 1 year ago
I keep adding. About to be unleashed soon.$$$
👍️0
Louman Louman 1 year ago
Shares getting locked up. RSV vaccine in the pipeline. Could it get FDA fast track?
👍️0
Jess070283 Jess070283 1 year ago
Squeeze!!!!
👍️0
makinezmoney makinezmoney 1 year ago
$ICVX: Jan 2023 $10 Calls were $0.20 yesterday.................


Just hit $4.40 !!!!!!!!!!!!!!!!


WOW................... a beautiful 22x bagger !!!!!!!!!!!!!!


Thank you


GO $ICVX
👍️0
makinezmoney makinezmoney 1 year ago
$ICVX: $13 baby................... people missing this


Oh welllllllllllllllllllllllll



Lets get to $25......... i know you can, like that MonkePox call I made in JULY


GO $ICVX
👍️0
makinezmoney makinezmoney 1 year ago
$ICVX: BOOMmmmmmmmmm .......... now 10.30

Whatta move since the initial call

Everyone missed the RSV news from a couple days ago

Icosavax Reports Positive Durability Data for VLP Vaccine Candidate IVX-121 Against RSV at Six-Month Timepoint
December 13 2022 - 04:05PM
GlobeNewswire Inc.
Alert
Print
Share On Facebook

Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases and a vision of creating pan-respiratory vaccines for older adults, today provided a six-month immunogenicity update from its Phase 1/1b trial of IVX-121 against Respiratory Syncytial Virus (RSV). These new data demonstrate a sustained neutralizing antibody (nAb) response against RSV, lasting for at least six months after a single administration of IVX-121.
“We are delighted to share the six-month immunogenicity data from our Phase 1/1b trial of IVX-121. The potential for long-lasting immune responses was part of our founding hypothesis and preclinical rationale for developing combination VLP vaccines, so it is exciting to see this supportive initial clinical data on durability from our platform,” said Adam Simpson, Chief Executive Officer of Icosavax. “We continue to believe that there is a need for better vaccines, in particular the potential for combination respiratory vaccines with longer-lasting protection and low reactogenicity.”

IVX-121 (RSV) Phase 1/1b six-month immunogenicity update

IVX-121 continued to be generally well-tolerated with no safety concerns observed in this six-month follow up and no vaccine related serious adverse events (SAEs).

Data shown and described below illustrate the ongoing neutralizing antibody responses to a single administration of IVX-121 at three dosage levels (25, 75, 250 µg), in the groups without adjuvant. Samples were taken at baseline, day 28, and day 180, with neutralizing antibodies measured in international units (IU/mL) using the WHO international reference standard.


Lets go $TMNA next


GO $ICVX
👍️ 1
makinezmoney makinezmoney 1 year ago
$ICVX: DAMMmmmmnnnnnn now 7.80


MASSSIVE mmove into the close.


Very impressive


GO $ICVX
👍️0
makinezmoney makinezmoney 1 year ago
$ICVX: Helluva move today........ now 6.90


Evercore ISI has a $18 target on it.......... bounced off that bottom, some squeezing going on.

Currently trading at 5.91 Cash/share


Hmmmmmmmmmmmmmm.............. interesting move.

Beaten down HARDDDDDDDDDddd this year


WOW


GO $ICVX
👍️0

Your Recent History

Delayed Upgrade Clock